Ausgabe 4/2010
Inhalt (9 Artikel)
Editorial
Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality
Jean-François Morère
Original Research
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
David Rossi, Donatella Dennetta, Marcello Ugolini, Vincenzo Catalano, Paolo Alessandroni, Paolo Giordani, Anna Maria Baldelli, Virginia Casadei, Francesco Graziano, S. Luzi Fedeli
Original Research
Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice
Yixiang Wang, Ling Dong, Qingwei Bi, Xiao Li, Dengcheng Wu, Xiyuan Ge, Xiaoxia Zhang, Jia Fu, Chengfei Zhang, Cunyu Wang, Shenglin Li
Review
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992
James F. Spicer, Sarah M. Rudman
Review
Targeting mTOR in cancer: renal cell is just a beginning
Hamdy Azim, Hatem A. Azim Jr., Bernard Escudier
Review
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy
James J. Driscoll, Roopa DeChowdhury
Day-to-Day Practice
Use of rituximab in three children with relapsed/refractory Burkitt lymphoma
Sinan Akbayram, Murat Doğan, Cihangir Akgün, Fatih Erbey, Hüseyin Çaksen, Ahmet Faik Öner
Day-to-Day Practice
Tufted hair folliculitis in a woman treated with trastuzumab
Ilana S. Rosman, Milan J. Anadkat